relenopride
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01523184)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 4 (5-HT4) receptorAGONIST
HTR4 agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(N)c(Cl)cc1C(=O)NCC1CCN(CC[C@H](OC(N)=O)c2ccc(F)cc2)CC1- Mol. weight
- 492.98 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544975 ↗
Also known as
- carbamic acid 3-(4-((4-amino-5-chloro-2-methoxybenzoylamino)methyl)piperidin-1-yl)-1-(4-fluorophenyl)propyl ester
- relenopride
- relenopride
- relenopride
- ykp10811
- ykp10811
- ykp10811
- ykp-10811
- ykp-10811
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02082457 | Phase 2 | Dec 1, 2013 | SK Chemicals, Yonsei University |
| NCT01989234 | Phase 2 | Oct 1, 2013 | Arvelle |
| NCT01523184 | Phase 2 | Mar 1, 2012 | Arvelle, Mayo Clinic |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arvelle | For profit | 2 | 2 | 1 | 2012 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2012 |
| SK Chemicals | For profit | 1 | 1 | 1 | 2013 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1